Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

(MedPage Today) -- CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS...